| 10.1933 0.463 (4.76%) | 11-11 15:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.38 | 1-year : | 32.99 |
| Resists | First : | 20.88 | Second : | 28.25 |
| Pivot price | 14.88  |
|||
| Supports | First : | 8.96 | Second : | 7.45 |
| MAs | MA(5) : | 11.02 |
MA(20) : | 17.68 |
| MA(100) : | 14.21 |
MA(250) : | 11.79 |
|
| MACD | MACD : | -2.7 |
Signal : | -1.6 |
| %K %D | K(14,3) : | 4.2 |
D(3) : | 4.7 |
| RSI | RSI(14): 32.3 |
|||
| 52-week | High : | 28.25 | Low : | 5.9 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NTLA ] has closed above bottom band by 27.5%. Bollinger Bands are 209.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 38 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.13 - 11.19 | 11.19 - 11.25 |
| Low: | 9.51 - 9.58 | 9.58 - 9.65 |
| Close: | 9.63 - 9.73 | 9.73 - 9.83 |
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Tue, 11 Nov 2025
Intellia Therapeutics (NTLA) Downgraded to 'Hold' by Jones Tradi - GuruFocus
Tue, 11 Nov 2025
Intellia Therapeutics (NTLA): Assessing Valuation After FDA Clinical Hold on Lead Gene-Editing Program - Yahoo Finance
Tue, 11 Nov 2025
What 21 Analyst Ratings Have To Say About Intellia Therapeutics - Benzinga
Sat, 08 Nov 2025
Patient Treated in Trial for Intellia’s Transthyretin Amyloidosis Gene Editing Therapy Nex-Z Dies - CGTLive®
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 107 (M) |
| Shares Float | 102 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 88.2 (%) |
| Shares Short | 30,900 (K) |
| Shares Short P.Month | 34,140 (K) |
| EPS | -4.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.78 |
| Profit Margin | 0 % |
| Operating Margin | -772.2 % |
| Return on Assets (ttm) | -30.7 % |
| Return on Equity (ttm) | -57 % |
| Qtrly Rev. Growth | 104.8 % |
| Gross Profit (p.s.) | -3.61 |
| Sales Per Share | 0.49 |
| EBITDA (p.s.) | -4.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -419 (M) |
| Levered Free Cash Flow | -178 (M) |
| PE Ratio | -2.13 |
| PEG Ratio | 0 |
| Price to Book value | 1.47 |
| Price to Sales | 20.27 |
| Price to Cash Flow | -2.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|